Released on:
February 24, 2025
Expires on:
February 24, 2026
Target Audience
This activity is intended for neurologists, nurse practitioners (NPs), physician associates (PAs), nurses, pharmacists, and other members of the health care team caring for patients with multiple sclerosis (MS).
Learning Objectives
At the conclusion of this activity, participants should be better able to:
- Apply strategies as a multidisciplinary team to effectively communicate with and educate women of childbearing potential about family planning
- Identify factors that should be considered and discussed when making choices about disease-modifying therapy (DMT) for a woman of childbearing potential
- Employ evidence-based considerations and strategies for discontinuing and/or switching DMT in a patient who wishes to become pregnant
- Analyze data on the use of available DMTs during pregnancy
- Review currently available evidence on the effects of pregnancy and the postpartum state on MS disease activity
- Review evidence and considerations related to the use of DMTs in the postpartum period and during breastfeeding
Faculty
Riley Bove, MD, FAAN
Associate Professor
UCSF Weill Institute for Neurosciences
San Francisco, California
Marijean Buhse, PhD, RN, ANP-BC, MSCN, FAAN
Stony Brook University/South Shore Neurologic
Long Island, New York
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation
Physicians
The CMSC designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The CMSC designates this activity for a maximum of 0.75 nursing continuing professional development (NCPD) credit (0.75 in the area of pharmacology).
Pharmacists
This knowledge-based activity, UAN: JA4008165-9999-25-003-H01-P, qualifies for 0.75 contact hours (.075 CEUs) of continuing pharmacy education credit.
Interprofessional Continuing EducationThis activity was planned by and for the health care team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
All other health care professionals completing this course will be issued a statement of participation.
Request for Credit
Upon completion of the evaluation, your certificate will be emailed to you.
Disclosures of Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME’s) Standards for Integrity and Independence in Continuing Education, CMSC and Catamount Medical Education require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and Catamount Medical Education mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and Catamount Medical Education seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and Catamount Medical Education are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
Faculty Disclosures
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Riley Bove, MD, FAAN
Consulting/Advisory Fees: Alexion Pharmaceuticals, Inc; Amgen Inc; Cadenza Bio; EMD Serono; Sanofi; TG Therapeutics, Inc
Contracted Research: Biogen; Genentech Inc; Lilly USA, LLC; Novartis Pharmaceuticals Corporation
Marijean Buhse, PhD, RN, ANP-BC, MSCN, FAAN
Speakers Bureau: Biogen
Activity Staff Disclosures
Laurie Scudder, DNP, NP, served as planner and reviewer and has disclosed no relevant financial relationship.
All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at The Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.
The planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the International Organization of Multiple Sclerosis Nurses who control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, CE committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.
How to Participate in This Activity and Obtain CE Credit
There are no fees for participating and receiving credit for this activity. During the period that the activity is available for credit, participants must:
- Read the CE information
- Complete the presurvey
- View the content
- Complete the postsurvey and the evaluation form
Upon completion of the postsurvey and evaluation, your certificate will be emailed to you.
Our Policy On Privacy
The Consortium of Multiple Sclerosis Centers and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the posttest and evaluation results for CE credit. This information is provided to activity collaborators for the purposes of CE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information.
Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.
Disclosure of Unlabeled Use
CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For questions about this activity, please contact Catamount Medical Education at [email protected].